Skip to main content
. Author manuscript; available in PMC: 2011 Apr 5.
Published in final edited form as: J Acquir Immune Defic Syndr. 2005 Feb;38(2):174–179. doi: 10.1097/01.qai.0000145351.96815.d5

TABLE 3.

Factors Associated With HIV Viral Load Below Detectable Level Among Patients Receiving HAART Treatment

No. Patients No. HIV Viral Load Undetectable (%) Univariate Analysis
Multivariate Analysis
OR P OR (95% CI) P
Gender
 Male 443 300 (68%)
 Female 155 115 (74%) 1.4 0.133 1.5 (0.9–2.3) 0.077
Age (y) when HAART started
 <31 133 88 (66%)
 31–40 265 176 (66%) 1.0 0.960 1.1 (0.71–1.8) 0.623
 41+ 198 151 (76%) 1.6 0.045 1.8 (1.1–3.1) 0.017
 Not known 2 0 (0%)
Exposure category
 Heterosexual contact 437 307 (70%)
 Homosexual contact 98 75 (77%) 1.4 0.215 1.9 (1.1–3.2) 0.023
 Other 63 33 (52%) 0.5 0.005 0.4 (0.2–0.6) 0.001
Baseline viral load test (copies/mL)
 <5000 78 57 (73%)
 5000+ 299 196 (66%) 0.7 0.209 0.7 (0.4–1.2) 0.170
 Not tested before 221 162 (73%) 1.0 0.969 0.8 (0.5–1.6) 0.569
 HAART (3 or more drugs)
 NRTI ± PI − NNRTI 260 166 (64%)
 NRTI + NNRTI − PI 312 229 (73%) 1.6 0.014 1.7 (1.2–2.6) 0.006
 NNRTI + PI ± NRTI 26 20 (77%) 1.9 0.188 2.0 (0.8–5.2) 0.168
Having mono/double therapy before starting HAART
 No 380 273 (72%)
 Yes 218 142 (65%) 0.7 0.087 0.7 (0.5–1.0) 0.067